A Phase 1, Randomized, Investigator- and Participant-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, and Pharmacokinetics of LY4515100 in Healthy Participants
Eli Lilly and Company
Summary
The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 30 days and will include six overnight stays.
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring. * Have a body mass index within the range of 18.5 to 32.0 kilograms per square meter (kg/m\^2) (inclusive). * Individuals of childbearing potential (IOCBP) are excluded from this trial. * Individuals not of childbearing potential (INOCBP) may participate in this trial. Exclusion Criteria: * Have donated 500 milliliters (mL) of blood within 30 days prior to dosing. * Have participated within the last 30 days in a…
Interventions
- DrugLY4515100 via SAD
given orally
- DrugLY4515100 via MAD
given orally
Location
- Fortrea Clinical Research UnitDallas, Texas